Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe, et al.
Anticancer Research (2019) Vol. 39, Iss. 9, pp. 5195-5201
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh, Soyeon Kim, Bhumsuk Keam, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 92
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Kaijian Zhou, Shu Guo, Fei Li, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 76
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 14
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain
International Immunopharmacology (2024) Vol. 143, pp. 113365-113365
Closed Access | Times Cited: 8
Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11887-11887
Open Access | Times Cited: 20
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy
Sajjad Ahmadpour, Mohammad Amin Habibi, Farzaneh Sadat Ghazi, et al.
Cancer Treatment and Research Communications (2024) Vol. 40, pp. 100823-100823
Open Access | Times Cited: 6
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Jacob J. Orme, Elizabeth Ann L. Enninga, Fabrice Lucien-Matteoni, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001113-e001113
Open Access | Times Cited: 47
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Yusuke Omura, Yuji Toiyama, Yoshinaga Okugawa, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 12, pp. 2533-2546
Open Access | Times Cited: 45
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial
Hisato Kawakami, Yu Sunakawa, Eisuke Inoue, et al.
European Journal of Cancer (2023) Vol. 184, pp. 10-20
Closed Access | Times Cited: 16
Non-cytomembrane PD-L1: An atypical target for cancer
Honggang Ying, Xiaozhen Zhang, Yi Duan, et al.
Pharmacological Research (2021) Vol. 170, pp. 105741-105741
Open Access | Times Cited: 32
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1929-1929
Open Access | Times Cited: 28
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Ádám Széles, Tamás Fazekas, Szilárd Váncsa, et al.
Cancer Immunology Immunotherapy (2022) Vol. 72, Iss. 5, pp. 1061-1073
Open Access | Times Cited: 21
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Lin Chen, Yuqing Chao, Wenjing Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
Jie Yao, Xuwen Lin, Xin Zhang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 4
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial
Jacob J. Orme, Henan Zhang, Prashanth Lingamaneni, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
Tudor Mocan, Maria Iacobescu, Iuliana Nenu, et al.
International Immunopharmacology (2021) Vol. 94, pp. 107467-107467
Closed Access | Times Cited: 25
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Carlos Zamora, Geòrgia Anguera, M. Riudavets Melià, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 8, pp. 1823-1835
Open Access | Times Cited: 16
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
Kazumasa Oya, Yoshiyuki Nakamura, Larina Tzu‐Wei Shen, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 807-815
Closed Access | Times Cited: 3
Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Ningning Zhang, Jianlan Chang, Ping Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
Carla Chiarucci, Sara Cannito, Maria Grazia Daffinà, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 361-361
Open Access | Times Cited: 24
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors
Kiyohiro Ando, Kazuyuki Hamada, Midori Shida, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 337-348
Open Access | Times Cited: 24
Soluble PD-L1 as a Predictive Biomarker in Lung Cancer: A Systematic Review and Meta-Analysis
Yang Cheng, Chong Wang, Yan Wang, et al.
Future Oncology (2021) Vol. 18, Iss. 2, pp. 261-273
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top